Safe Harbor Statements Certain data in this Presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this Presentation. Such data involves risks and uncertainties ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-39138 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | 84 ...

Financial Performance - The company incurred net losses of $24.5 million and $21.6 million for the nine months ended September 30, 2022 and 2021, respectively[130]. - The accumulated deficit of the company reached $91.8 million as of September 30, 2022[130]. - The net loss for Q3 2022 was $11.9 million, compared to a net loss of $3.4 million in Q3 2021, reflecting a 248% increase in losses[147]. - The company recognized a net loss of $24.5 million for the nine months ended September 30, 2022, compared to a net loss of $21.6 million for the same period in 2021, a 13% increase in losses[156]. - The company has incurred significant losses and negative cash flows from operations since inception, indicating a substantial doubt about its ability to continue as a going concern[131]. Cash Position - As of September 30, 2022, the company had cash and cash equivalents of $51.0 million, which is insufficient to fund operations in the foreseeable future[131]. - As of September 30, 2022, cash and cash equivalents totaled $51.0 million, with no outstanding debt[189]. - Net cash used in operating activities was $33.2 million for the nine months ended September 30, 2022, compared to $19.1 million for the same period in 2021[173]. - Cash provided by financing activities was less than $0.1 million for the nine months ended September 30, 2022, compared to $101.9 million in 2021[178][179]. Research and Development - The lead product candidate, JSP191, is in clinical development and aims to initiate a registrational clinical study in acute myeloid leukemia (AML) patients by the end of Q1 2023[116]. - Initial results from a Phase 1 clinical trial of JSP191 showed that 0.6 mg/kg conditioning was well-tolerated, with all 24 patients achieving successful primary engraftment[121]. - The FDA granted rare pediatric disease designation and orphan drug designation to JSP191 for conditioning treatment prior to hematopoietic stem cell transplantation[120]. - The company plans to evaluate JSP191 as a therapeutic for lower-risk myelodysplastic syndrome (MDS) patients who are refractory to erythropoiesis-stimulating agents[123]. - The company has entered into a clinical collaboration with Stanford University to study JSP191 in patients with Fanconi anemia, with initial results showing 100% donor chimerism[122]. - The company intends to expand its pipeline to include other novel stem cell therapies based on immune modulation, graft engineering, and cell or gene therapies[116]. Operating Expenses - Research and development expenses increased by $1.8 million, from $7.2 million in Q3 2021 to $9.0 million in Q3 2022, representing a 26% increase[149]. - General and administrative expenses rose by $0.8 million, from $2.9 million in Q3 2021 to $3.7 million in Q3 2022, a 27% increase[152]. - Total operating expenses for Q3 2022 were $12.7 million, up from $10.1 million in Q3 2021, marking a 26% increase[147]. - Total operating expenses increased by $12.7 million, from $24.8 million for the nine months ended September 30, 2021, to $37.4 million for the same period in 2022, representing a 51% increase[156]. - Research and development expenses rose by $8.6 million, from $16.8 million for the nine months ended September 30, 2021, to $25.3 million for the same period in 2022, a 51% increase[158]. - General and administrative expenses increased by $4.1 million, from $8.0 million for the nine months ended September 30, 2021, to $12.1 million for the same period in 2022, a 52% increase[161]. Other Financial Information - Other income, net increased by $9.8 million, from $3.2 million for the nine months ended September 30, 2021, to $13.0 million for the same period in 2022, a 309% increase[162]. - The change in fair value of earnout liability decreased by 93%, from $6.2 million in Q3 2021 to $0.4 million in Q3 2022[147]. - The company has contractual obligations of $1.1 million within the next 12 months and $3.4 million for the remainder of the lease term under the amended lease agreement[183]. - The company does not currently have a marketing or sales organization, which will lead to significant commercialization expenses if regulatory approval is obtained[135]. - The ongoing COVID-19 pandemic may disrupt clinical trials and supply chains, impacting the company's financial performance and operations[138]. Market and Economic Conditions - Historical fluctuations in interest rates have not been significant, and a hypothetical 10% change would not materially affect the financial statements[189]. - Foreign currency transaction gains and losses have not been material, and the company does not have a formal hedging program[190]. - Inflation has not had a material effect on the interim condensed consolidated financial statements[191].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | 84-2984849 | | --- | --- | | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | 84-2984849 | | --- | --- | | ...

Financial Performance - The company reported net losses of $30.6 million and $31.7 million for the years ended December 31, 2021 and 2020, respectively, with an accumulated deficit of $67.5 million as of December 31, 2021[475]. - The company has not generated any revenue from product sales and expects to incur significant losses as it continues to seek regulatory approvals for its product candidates[474]. - The company reported a net loss of $30.6 million for 2021, a slight improvement from a net loss of $31.7 million in 2020, reflecting a 3% decrease[509]. - Total operating expenses for 2021 were $36.8 million, up from $20.7 million in 2020, marking a 78% increase[509]. - The company incurred net cash used in operating activities of $33.7 million for the year ended December 31, 2021, compared to $18.3 million for 2020[531][532]. - The company had net operating loss carryforwards of approximately $53.1 million for federal income tax purposes and $45.4 million for state income tax purposes as of December 31, 2021[558]. Cash Position and Financing - Cash and cash equivalents were $84.7 million as of December 31, 2021, which may not be sufficient to fund operations in the foreseeable future, indicating substantial doubt about the company's ability to continue as a going concern[476]. - As of December 31, 2021, the company had $84.7 million in cash and cash equivalents, following net cash proceeds of $95.3 million from the Business Combination[519]. - The company raised $101.0 million in financing activities for the year ended December 31, 2021, primarily from the Business Combination and PIPE Financing, compared to $11.3 million in 2020[536][537]. - The company expects to finance future cash needs through public or private equity or debt financings, collaborations, or a combination of these approaches[522]. - The company anticipates that its ability to raise additional funds may be adversely impacted by negative global economic conditions and disruptions in credit and financial markets[522]. Research and Development - The lead product candidate, JSP191, is in clinical development for severe combined immunodeficiency (SCID) and has shown promising preliminary results, with six out of nine patients achieving donor engraftment[464]. - JSP191 has received rare pediatric disease designation and orphan drug designation from the FDA for its use as a conditioning treatment prior to hematopoietic stem cell transplantation[465]. - The company is also evaluating JSP191 in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with initial results showing successful engraftment in all patients[466]. - The company plans to expand its pipeline to include other novel stem cell therapies based on immune modulation and gene therapies, aiming to improve the efficacy and safety of treatments[461]. - The eHSC platform is designed to enhance stem cell engraftment and survival, with initial preclinical experiments indicating potential advantages over existing therapies[470]. - The company has entered into collaborations with Stanford University and the National Institutes of Health to study JSP191 in various conditions, including Fanconi anemia and sickle cell disease[467]. - The company experienced slower patient enrollment in clinical trials due to the COVID-19 pandemic, impacting its clinical development timelines[482]. - The company anticipates significant future research and development expenses as it advances product candidates and expands its pipeline[504]. Expenses and Costs - Research and development expenses increased by $9.5 million, from $15.9 million in 2020 to $25.4 million in 2021, representing a 60% increase[511]. - External costs for CRO, CMO, and other third-party preclinical studies and clinical trials rose by $6.5 million, from $8.8 million in 2020 to $15.3 million in 2021, a 74% increase[511]. - General and administrative expenses increased by $6.6 million, from $4.8 million in 2020 to $11.4 million in 2021, a 138% increase[513]. - The company expects significant commercialization expenses if regulatory approval is obtained for product candidates, including costs related to sales, marketing, manufacturing, and distribution[480]. - The company expects general and administrative expenses to continue rising due to increased personnel and compliance costs associated with being a public company[507]. Stock and Equity - The PIPE Financing raised $100 million through the issuance of 10,000,000 shares of Class A Common Stock at $10.00 per share[484]. - The company has authorized 490,000,000 shares of voting common stock, with 36,559,092 shares issued and outstanding as of December 31, 2021[489]. - Stock-based compensation expense recorded was $1.0 million for the year ended December 31, 2021, compared to $1.2 million for 2020[553]. - As of December 31, 2021, total unrecognized stock-based compensation expense was $1.5 million, expected to be recognized over a remaining weighted-average period of 2.6 years[553]. Agreements and Obligations - The company has a license agreement with Amgen for JSP191, which includes an option to negotiate a definitive license with Stanford for related intellectual property[491][492]. - Under the Stanford License Agreement, the company is obligated to pay up to $9.0 million in milestone payments and low single-digit royalties on net sales of licensed products[496]. - The company has entered into various collaboration and clinical trial agreements, including with Stanford University and the National Cancer Institute, to study JSP191 for different indications[498][500]. - The company has lease commitments of $0.7 million for the next 12 months and $2.7 million for the remainder of the lease term, with an additional commitment of $1.8 million for newly leased space[525]. - The company entered into a sponsored research agreement with Stanford, committing to pay a total of $0.9 million over approximately three years upon achieving clinical milestones[526]. - The company has a contingent earnout liability estimated at $5.7 million as of December 31, 2021, down from an estimated fair value of $15.0 million at the closing of the Business Combination[544]. - The company has contractual obligations with CROs and CMOs for clinical trials and manufacturing, with no non-cancellable obligations as of December 31, 2021[523][524]. Market and Economic Conditions - The company will remain an emerging growth company until certain revenue or market value thresholds are met[562]. - Foreign currency transaction gains and losses have not been material to the consolidated financial statements[564]. - The fair value of common stock is estimated based on the closing quoted market price on the Nasdaq Capital Market[555]. - The company intends to maintain its portfolio of cash equivalents in institutional market funds composed of U.S. Treasury securities to minimize interest rate risk[563].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-2984849 (State or other j ...

Financial Performance - For the three months ended June 30, 2021, the company reported a net loss of $3,569,534, which includes general and administrative expenses of $562,032 and a change in fair value of the warrant liability of $3,010,000[139] - For the six months ended June 30, 2021, the company had a net income of $1,928,537, primarily due to a change in fair value of the warrant liability of $2,700,000 and interest income of $4,971[140] - Cash used in operating activities for the six months ended June 30, 2021, was $678,626, reflecting adjustments for noncash income from the change in fair value of warrant liability[145] Cash and Securities - As of June 30, 2021, the company had cash and marketable securities in the Trust Account totaling $100,126,108, with interest income used to pay taxes[147] - As of June 30, 2021, the company had cash of $309,730 held outside the Trust Account, intended for identifying and evaluating target businesses[148] Initial Public Offering (IPO) - The company completed its Initial Public Offering on November 22, 2019, raising gross proceeds of $100,000,000 from the sale of 10,000,000 Units at $10.00 per Unit[143] - The company incurred $5,944,772 in transaction costs related to the Initial Public Offering, including $2,000,000 in underwriting fees[144] - The company issued common stock warrants in connection with its Initial Public Offering and private placement, recognized as derivative liabilities at fair value[161] Business Combination - The company entered into a business combination agreement with Jasper Therapeutics, Inc., which includes a PIPE Financing of 10,000,000 shares at $10.00 per share, totaling $100.0 million[136] - The company has until November 22, 2021, to complete a Business Combination, with potential liquidation if not achieved[151] Financial Instruments and Risks - The fair value of warrants from the Initial Public Offering was estimated using Monte Carlo simulations and public trading prices, while private placement warrants were estimated using a Modified Black Scholes Option Pricing Model[161] - The company adopted ASU 2020-06 effective January 1, 2021, which simplifies accounting for certain financial instruments, but it did not impact the condensed consolidated financial statements[162] - As of June 30, 2021, the company was not subject to any market or interest rate risk, with net proceeds from the Initial Public Offering invested in U.S. government treasury bills and money market funds[164] - The company believes there will be no material exposure to interest rate risk due to the short-term nature of its investments[164] Off-Balance Sheet Financing - The company has no off-balance sheet financing arrangements as of June 30, 2021, and does not participate in transactions that create relationships with unconsolidated entities[152]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-39138 AMPLITUDE HEALTHCARE ACQUISITION CORPORATION | Large accelerated filer | ☐ | Accelerated filer | ☐ | | -- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | Delaware | 84-2984849 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification Number) | | 1177 Avenue of th ...